Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by BLA submission and planned commercial launch. In addition to meeting guidance for NEXICART-2 enrollment completion and announcing topline NEXICART-2 results expected Q3 2026, Immix has onboarded chief medical officer, Richard Graydon. Graydon is a board-certified hematologist-oncologist with over 20 years of experience in clinical development, most recently at Merck (MRK).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma price target raised to $15 from $14 at Mizuho
- Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
- Immix Biopharma Amends ATM Offering to Raise Capital
- Immix Biopharma initiated with an Overweight at Morgan Stanley
- Immix Biopharma initiated with an Outperform at Citizens